CiteFacts · FDA Drug Shortages · FDA source
Rifampin Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Fresenius Kabi USA, LLC | Rifampin, Injection, 600 mg (NDC 63323-351-20) | Unavailable | 08/04/2026 |
| Mylan Institutional, a Viatris Company | Rifampin, Injection, 600 mg (NDC 67457-445-60) | Unavailable | 08/20/2026 |
| Sanofi-Aventis U.S. LLC | Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Unavailable | 06/22/2026 |
| Sanofi-Aventis U.S. LLC | Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | Not stated | 04/20/2026 |
Source facts
Grouped generic ingredient: Rifampin Injection · 4 package records · Latest FDA row update: 08/20/2026
Therapeutic categories: Anti-Infective
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.